Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibitors of PARP: Number crunching and structure gazing
Johannes Rudolph, Karen Jung, Karolin Luger
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 11
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

ADP-ribosylation from molecular mechanisms to therapeutic implications
Marcin J. Suskiewicz, Evgeniia Prokhorova, J.G.M. Rack, et al.
Cell (2023) Vol. 186, Iss. 21, pp. 4475-4495
Open Access | Times Cited: 75
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
Michalis Petropoulos, Angeliki Karamichali, Giacomo G. Rossetti, et al.
Nature (2024) Vol. 628, Iss. 8007, pp. 433-441
Open Access | Times Cited: 58
Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
Ashwin Ragupathi, Manrose Singh, Alexis M. Perez, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 53
PARP1 associates with R-loops to promote their resolution and genome stability
Natalie Laspata, Parminder Kaur, Sofiane Y. Mersaoui, et al.
Nucleic Acids Research (2023) Vol. 51, Iss. 5, pp. 2215-2237
Open Access | Times Cited: 50
Development of PARP inhibitors in advanced prostate cancer
María T. Bourlon, Paola Valdez, Elena Castro
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 21
Modular antibodies reveal DNA damage-induced mono-ADP-ribosylation as a second wave of PARP1 signaling
Edoardo José Longarini, Helen Dauben, Carolina Locatelli, et al.
Molecular Cell (2023) Vol. 83, Iss. 10, pp. 1743-1760.e11
Open Access | Times Cited: 38
Targeting the DNA damage response for cancer therapy
Nicola J. Curtin
Biochemical Society Transactions (2023) Vol. 51, Iss. 1, pp. 207-221
Open Access | Times Cited: 35
Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
Marie-France Langelier, Xiaohui Lin, Shan Zha, et al.
Science Advances (2023) Vol. 9, Iss. 12
Open Access | Times Cited: 32
ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification
Élise Rouleau-Turcotte, John M. Pascal
Journal of Biological Chemistry (2023) Vol. 299, Iss. 12, pp. 105397-105397
Open Access | Times Cited: 25
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
Ke Cong, Nathan J. MacGilvary, Silviana Lee, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells
Petar-Bogomil Kanev, Sylvia Varhoshkova, Irina Georgieva, et al.
Cell Reports (2024) Vol. 43, Iss. 5, pp. 114234-114234
Open Access | Times Cited: 10
Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance
Limin Wang, Pingyuan Wang, X. T. Chen, et al.
EMBO Molecular Medicine (2023) Vol. 15, Iss. 3
Open Access | Times Cited: 21
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models
Chun Wai Wong, Christos Evangelou, Kieran N. Sefton, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 21
Inactive PARP1 causes embryonic lethality and genome instability in a dominant-negative manner
Zhengping Shao, Brian J. Lee, Hanwen Zhang, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 31
Open Access | Times Cited: 17
The dynamics and regulation of PARP1 and PARP2 in response to DNA damage and during replication
Hanwen Zhang, Shan Zha
DNA repair (2024) Vol. 140, pp. 103690-103690
Closed Access | Times Cited: 8
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers
Rebecca Kristeleit, Alexandra Léary, Ana Oaknin, et al.
British Journal of Cancer (2024) Vol. 131, Iss. 5, pp. 820-831
Open Access | Times Cited: 8
Structural dynamics of DNA strand break sensing by PARP-1 at a single-molecule level
Anna Sefer, Eleni Kallis, Tobias Eilert, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 27
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
Jaromir Hunia, Karol Gawalski, Aleksandra Szredzka, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 23
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective
Nicoletta Cordani, Tommaso Bianchi, Luca Carlofrancesco Ammoni, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 11890-11890
Open Access | Times Cited: 15
Switch-like compaction of poly(ADP-ribose) upon cation binding
Mohsen Badiee, Adam Kenet, Laura R. Ganser, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 19
Open Access | Times Cited: 13
Positioning Loss of PARP1 Activity as the Central Toxic Event in BRCA-Deficient Cancer
Nathan J. MacGilvary, Sharon B. Cantor
DNA repair (2024) Vol. 144, pp. 103775-103775
Open Access | Times Cited: 5
First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States
Rana R. McKay, Alicia K. Morgans, Neal D. Shore, et al.
Cancer Treatment Reviews (2024) Vol. 126, pp. 102726-102726
Open Access | Times Cited: 4
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Louise Kostos, Ben Tran, Arun Azad
Drugs (2024) Vol. 84, Iss. 9, pp. 1093-1109
Open Access | Times Cited: 4
Single-molecule analysis of PARP1-G-quadruplex interaction
Paras Gaur, Fletcher E. Bain, Riaz Meah, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Impact of a Cancer-Associated Mutation on Poly(ADP-ribose) Polymerase1 Inhibition
Naga Shanmugam, Shubham Chatterjee, G. Andrés Cisneros
The Journal of Physical Chemistry B (2025)
Open Access
Page 1 - Next Page

Scroll to top